Partnership expansion will help strengthen Samsung Bioepis and Teva Pharmaceutical’s global market position and respective pipelines.
Samsung Bioepis and Teva Pharmaceutical have broadened their biosimilar-focused partnership, adding up to six potential candidates.
This involves two confirmed investigational biosimilars, SB41, a biosimilar candidate referencing Fasenra (benralizumab) and SB44, a biosimilar candidate referencing Ilaris (canakinumab), alongside four additional asset options.
It builds on their initial licensing, development and commercialisation agreement made in March, which planned to increase Sandoz’s pipeline by up to 32 biosimilar candidates.
Both companies have already benefitted from this decision, including successful commercialisation of monoclonal antibody Epysqli (eculizumab) in the US.
Richard Francis, President and CEO of Teva said: “This global multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S.
”By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world.”
“By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world”
Richard Francis, President and CEO of Teva
Under the expanded agreement, Samsung Bioepis will lead development through to manufacture, while Teva will manage global commercialisation.
Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis, added: “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”
Meanwhile, in August Sandoz agreed a $322 million collaboration deal with Shanghai Henlius Biotech to advance up to 10 biosimilars, also intended to expand its own pipeline. This summer, Sandoz invested in a new development centre in Slovenia to capitalise on the upcoming “biosimilar golden age”.
No comments yet